The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 1/2 study of ONCT-534, a dual-action androgen receptor inhibitor (DAARI), in patients with metastatic castration-resistant prostate cancer.
 
Evan Y. Yu
Consulting or Advisory Role - AADi; Advanced Accelerator Applications; Bayer; Janssen; Merck; Oncternal Therapeutics
Research Funding - Bayer (Inst); Blue Earth Diagnostics (Inst); Daiichi Sankyo (Inst); Dendreon (Inst); Lantheus Medical Imaging (Inst); Merck (Inst); Seagen (Inst); Surface Oncology (Inst); Taiho Pharmaceutical (Inst); Tyra Biosciences (Inst)
 
Salim Yazji
Employment - Oncternal Therapeutics, Inc
Leadership - Oncternal Therapeutics, Inc
Stock and Other Ownership Interests - Oncternal Therapeutics, Inc
 
Yisrael Katz
Employment - Oncternal Therapeutics; Viracta Therapeutics
Stock and Other Ownership Interests - Exelixis; Viracta Therapeutics
 
Elisabeth Coates
Employment - Oncternal Therapeutics, Inc
 
Luke T. Nordquist
No Relationships to Disclose
 
Andrae Lavon Vandross
Employment - Next Oncology; Texas Oncology
Research Funding - Abbvie (Inst); Ascentage Pharma (Inst); BiOneCure (Inst); Chugai Pharma (Inst); Deciphera (Inst); Exelixis (Inst); Immunomedics (Inst); IMPAC Medical Systems (Inst); Kirilys Therapeutics (Inst); Kura Oncology (Inst); Lyvgen Biopharma (Inst); Medikine (Inst); Nanjing (Inst); NGM Biopharmaceuticals (Inst); Nitto BioPharma (Inst); OncoResponse (Inst); PMV Pharma (Inst); Sirnaomics (Inst); Tachyon Therapeutics (Inst); Teon Therapeutics (Inst); Xilio Therapeutics (Inst); Yufan Biotechnologies (Inst); ZielBio (Inst)
 
Mohamad Adham Salkeni
Employment - Next Oncology; Virginia Cancer Specialists
Stock and Other Ownership Interests - Next Oncology
Honoraria - Healthcasts
Research Funding - Agenus (Inst); BeiGene (Inst); Boehringer Ingelheim (Inst); Bolt Biotherapeutics (Inst); Chugai Pharma (Inst); CrystalGenomics (Inst); IDEAYA Biosciences (Inst); Kronos Bio (Inst); MBrace Therapeutics (Inst); Oncternal Therapeutics (Inst); Prelude Therapeutics (Inst); Stemline Therapeutics (Inst); Takeda (Inst); Tarus Therapeutics (Inst)
 
Joshua Michael Lang
Stock and Other Ownership Interests - Salus Discovery
Consulting or Advisory Role - 4D Pharma; 4D Pharma; Arvinas; AstraZeneca; Gilead Sciences; Immunomedics; Janssen; Pfizer/Astellas; Pfizer/Myovant; Sanofi
Research Funding - Agensys (Inst); Arvinas (Inst); Bristol-Myers Squibb (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Immunomedics (Inst); Janssen (Inst); Medivation (Inst)
Patents, Royalties, Other Intellectual Property - I am listed on the patent on a technology for rare cell capture and analysis. This technology has been licensed by Salus Discovery, LLC though no commercial products are available.
 
Peter Nelson
Consulting or Advisory Role - Astellas Pharma; Bristol-Myers Squibb; Janssen Oncology; Roche/Genentech
Research Funding - Genomic Health (Inst); Janssen Oncology
Expert Testimony - Venable
Travel, Accommodations, Expenses - Janssen Oncology
 
James Bradley Breitmeyer
Employment - Oncternal Therapeutics, Inc
Leadership - Oncternal Therapeutics, Inc; Otonomy; Zogenix
Stock and Other Ownership Interests - Oncternal Therapeutics, Inc; Oncternal Therapeutics, Inc (I); Otonomy; Zogenix
Patents, Royalties, Other Intellectual Property - Inventor on patent(s)
Travel, Accommodations, Expenses - Oncternal Therapeutics, Inc; Zogenix
 
Lawrence Fong
Stock and Other Ownership Interests - Actym Therapeutics; Alector; Atreca; BioAtla; Bolt Biotherapeutics; ImmunoGenesis; NGM Biopharmaceuticals; Nutcracker Therapeutics, Inc.; RAPT Therapeutics; Senti Biosciences; Sutro Biopharma
Consulting or Advisory Role - Actym Therapeutics; AstraZeneca; Atreca; BioAtla; Bolt Biotherapeutics; Bristol-Myers Squibb; Daiichi Sankyo/UCB Japan; Dendreon; EMD Serono; ImmunoGenesis; Innovent Biologics; Janssen Oncology; Merck; NGM Biopharmaceuticals; Nutcracker Therapeutics, Inc.; RAPT Therapeutics; Roche/Genentech
Research Funding - Abbvie (Inst); Amgen (Inst); Bavarian Nordic (Inst); Dendreon (Inst); Merck (Inst)
 
Johann S. De Bono
Honoraria - Amgen; Astellas Pharma; AstraZeneca; Bayer; Daiichi Sankyo; Genentech/Roche; GlaxoSmithKline; ImCheck therapeutics; Janssen Oncology; Merck Serono; Merck Sharp & Dohme; Pfizer; Sanofi
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Bayer; BioXCel therapeutics (Inst); Boehringer Ingelheim (Inst); CellCentric; Crescendo Biologics (Inst); Daiichi Sankyo; Dark Blue Therapeutics (Inst); Eisai; Genentech/Roche; Genmab; GlaxoSmithKline; Harpoon therapeutics; ImCheck therapeutics; Immunic Therapeutics; Janssen Oncology; Merck Serono; Merck Sharp & Dohme; MetaCurUm; Myricx Pharma; Novartis; Nurix (Inst); Oncternal Therapeutics; Orion; Pfizer (Inst); Qiagen; Sanofi Aventis GmbH (Inst); Sierra Oncology; Taiho Oncology; Takeda (Inst); Tango Therapeutics (Inst)
Speakers' Bureau - AstraZeneca
Research Funding - Amgen (Inst); Astellas Pharma (Inst); Astex Pharmaceuticals (Inst); AstraZeneca (Inst); Bayer (Inst); CellCentric (Inst); Crescendo Biologics (Inst); Daiichi Sankyo (Inst); Genentech/Roche (Inst); Genmab (Inst); GlaxoSmithKline (Inst); Harpoon (Inst); Immunic Therapeutics (Inst); Janssen (Inst); Merck Serono (Inst); Merck Sharp & Dohme (Inst); MetaCurUm (Inst); Myricx (Inst); Nurix (Inst); Oncternal Therapeutics (Inst); Orion (Inst); Pfizer (Inst); Sanofi Aventis GmbH (Inst); Taiho Pharmaceutical (Inst)
Patents, Royalties, Other Intellectual Property - Abiraterone Rewards to Inventors (Inst); CHK1 inhibitor (Inst); PARP inhibitors and DNA repair defects (Inst); Targeting of IL23 in prostate cancer (Inst)
Travel, Accommodations, Expenses - Amgen; Astellas Pharma; AstraZeneca; Bayer; Cellcentric; Daiichi Sankyo; Genentech/Roche; GlaxoSmithKline; Halda Therapeutics; Merck Serono; Merck Sharp & Dohme; Orion; Pfizer; Sanofi